Entities

Published member of Wavemaker 360’s 2024 Council of Strategic Advisors, advising on Post-Acute Care. Historical external council service is distinguished from current operating employment or investment partnership.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Foley & Lardner (Former). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Yusuke Matsumoto is Venture Capitalist (last confirmed own November2025 announcement) at SBIInvestmentCoLtd. The manager’s ownNovember25,2025 release identifies him as a venturecapitalist and reports his inclusion in the2026edition of the ForbesJapan investor ranking; the latest reviewed full corporate-director roster does not list an additional executive office for him.

Masanobu Kotake is Auditor at SBIInvestmentCoLtd. The manager’s corporate directory confirms this exact office asofJune30,2026. The company operates venture-capital funds spanning AI, robotics, healthcare and emerging technologies.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Blue of Florida. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners (Former). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Medtronic. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Powers Health Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Yukiko Kato is Executive Officer and Director at SBIInvestmentCoLtd. The manager’s corporate directory confirms this exact office asofJune30,2026. The company operates venture-capital funds spanning AI, robotics, healthcare and emerging technologies. Nikon’s official accelerator programme names her in its original mentor directory with an authentic portrait and historical DeputyGeneralManager/CVCDepartment position; currentmanagerdirector role is confirmed separately.

Teruhisa Nobori is Executive Officer and Director at SBIInvestmentCoLtd. The manager’s corporate directory confirms this exact office asofJune30,2026. The company operates venture-capital funds spanning AI, robotics, healthcare and emerging technologies.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Tomoyuki Nii is Executive Officer and Director at SBIInvestmentCoLtd. The manager’s corporate directory confirms this exact office asofJune30,2026. The company operates venture-capital funds spanning AI, robotics, healthcare and emerging technologies. His2024direct investor interview for the NordicAsianVentureAlliance identifies him as Director/ExecutiveOfficer and describes international investing, including quantumcomputing. The published original named portrait is fromthat2024interview.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Valencia Plastic Surgery. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Surgalign (Former). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Argenx. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: UT Health San Antonio. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation. UniversityMedicalPartners cardiologist independently confirmed in his own clinical professional profile, distinct from TaiwaniaCapital investmentmanagernamesake.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Pennant (Former). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Optum (Former). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation. Published member of Wavemaker 360’s 2023 Council of Strategic Advisors, advising on Government Sponsored Healthcare. Historical external council service is distinguished from current operating employment or investment partnership.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Jevan. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Go Dental Valencia. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Thermo Fisher (Former). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Pennant (Board). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Kaufman Hall (Former). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation. Published member of Wavemaker 360’s 2024 Council of Strategic Advisors, advising on Hospitals & Health Systems. Historical external council service is distinguished from current operating employment or investment partnership.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Sierra Imaging Associates Medical Group. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Cottage Health. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Aerinno. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Connor Group. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation. Published member of Wavemaker 360’s 2024 Council of Strategic Advisors, advising on Healthcare M&A. Historical external council service is distinguished from current operating employment or investment partnership. ConnorGroup partner and financial-due-diligence specialist identified in issuer2023advisoryannouncement; distinct profile from existing Norwegian HiveAutonomy qualityteam namesake.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Cottage Health. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Kaiser Permanente (Former). This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Mercer. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Ortho Illinois. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: Providence Holy Cross Medical Center. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: LUMDX. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: University Medical Partners. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation.

Venture-operations specialist supporting partner strategy, policies and business plans. Earlier Three-Sixty Advisory Group associate and clinical-record/EMR operations work. Holds UC San Diego leadership-of-healthcare-organizations master’s and Cal State Northridge political-science bachelor’s.

Portfolio-platform leader with prior work at AEA Investors and StartUp Health, building founder communities and portfolio support programmes. Holds NYU bachelor’s. Current role leads Wavemaker’s portfolio and platform.

AI researcher and entrepreneur, concurrently ReadoutAI CEO according to the manager’s current biography. Co-founded Evid Science, an AI literature-analysis company which the manager explicitly identifies as its portfolio investment; later served as Genesis Research president following acquisition. Holds Johns Hopkins computer-science bachelor’s and USC computer-science doctorate.

Healthcare investor who previously led StartUp Health’s ventures team and a New York family-office investment team. Earlier global-macro investing at Schroders. Holds London School of Economics bachelor’s and CFA designation. Current Wavemaker role is partner.

Investor and startup operator with prior strategic-finance roles at Carbon Health and Allbirds and healthcare equity-capital-markets work at Citi. Holds Harvard MBA and Chicago economics bachelor’s; manager’s current role is senior associate. Distinct from Lair East Labs cofounder Michelle Wang, whose primary biography describes a different Big Four accounting career; originalhomonymgraphpreserved.

Practicing Santa Barbara Cottage Hospital emergency physician with operating, quality-improvement and clinical IT experience. Holds USC medical degree, UCLA psychobiology bachelor’s and emergency training at LA County/USC. Named as a venture partner by the manager.

CPA and fund-administration specialist with prior work in venture fund administration, Netflix revenue management, Palm SEC reporting and Deloitte audit. The manager publishes fund-administration responsibility; its directory does not establish an internal investing-partner role.

Surgeon and healthcare-innovation executive; concurrently COO at Boston Health AI and CSO/CMO at REGENDO according to her current manager biography. Former Cedars-Sinai surgical innovation officer and general/endocrine surgeon. Holds Boston University medical and biomedical-engineering degrees; trained at Cedars-Sinai and UCSF. Current venture-partner affiliation does not imply those employers are automatically portfolio investments.

Healthcare strategist and operator with leadership experience in physician networks, hospitals, clinical research and investment. Previously served as strategy leader at Verity Health, physician-network CEO and executive at Cedars-Sinai; holds UCLA business bachelor’s. Current manager title is senior fund adviser rather than historical venture-partner wording.

Healthcare executive and founder with experience spanning providers, insurers and life sciences. Previously led Ernst & Young’s global healthcare practice and served as Ingenix CEO. Holds Missouri doctorate in health-systems engineering and master’s degrees in industrial engineering/public health, and Tufts mathematics/economics bachelor’s. SEC filings identify him as John G. Nackel. The official John profile and grid govern over the stale JAY GOSS filename attached to his separate original portrait.

Medtech specialist who held FDA leadership roles and later operating-company leadership within Danaher. Founded MedTech Color and serves as MedTech Impact Partners managing partner; teaches and researches medtech innovation at UCLA Anderson. Holds Virginia MBA and materials-science master’s and Lincoln physics bachelor’s.

Former University Hospitals CEO and Cedars-Sinai COO. Healthcare operating executive with board experience across public, private and nonprofit organizations. Holds Penn State bachelor’s in health planning/administration, Xavier health-administration master’s and NYU public-administration master’s. Current executive-in-residence role is separate from the dated2023/24 advisory-council chair roles. Published member of Wavemaker 360’s 2024 Council of Strategic Advisors, advising on Health Systems Council Chair. Historical external council service is distinguished from current operating employment or investment partnership. Published member of Wavemaker 360’s 2023 Council of Strategic Advisors, advising on Health Systems Council Chair. Historical external council service is distinguished from current operating employment or investment partnership.

Eiji Nakamura is Senior Managing Executive Officer and Director at SBIInvestmentCoLtd. The manager’s corporate directory confirms this exact office asofJune30,2026. The company operates venture-capital funds spanning AI, robotics, healthcare and emerging technologies.

The Lutheran Foundation for Long Term Living (LFLTL) is a Pennsylvania charitable private foundation based in Erie, EIN87-1874516, supporting dignity, independence and quality of life for people affected by illness, injury, disability or challenging socioeconomic circumstances. Its own history dates the founding leadership appointment and creation of its initial named grants to October14,2021; the about page says founded2021, while a conflicting homepage shorthand says2022. The foundation developed from the Lutheran Home for the Aged and LIFE Northwestern Pennsylvania’s home- and community-based elder-care work. Its charter permits charitable grants and program-related investments in for-profit organizations advancing its mission. Current named grant programs address long-term living, older homeless adults, music therapy, independence and life skills, community benefit, wish fulfillment and urgent crises. Public awarded-grant descriptions include autism services, dementia care, music therapy and rehabilitation for brain injury and stroke. Its latest publicly accessible2024 Form990-PF, filedSeptember19,2025, names eleven officers/directors, including MarkJ.Gusek as president/director and RobertJoyce as CFO/CIO; later primary statements corroborate Gusek as president and CEO and Joyce as CFO/CIO. Governance roles from the tax return are dated affiliations rather than an assumed2026 roster. Tombot’s June25,2026 announcement explicitly names the foundation as an investor in its closedUSD7M SeriesA3 financing for companion robotics; the individual allocation is undisclosed. Foundation assets, investment returns, charitable distributions and grant budgets are not external LP fund closings.

Dennis M W Michalak is named as director (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Floyd M Csir is named as director (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Jeanne H Tropper is named as director (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Mark J. Gusek is president and CEO of the Lutheran Foundation for Long Term Living, appointed founding president and CEO on October 14, 2021. Gannon University describes more than 25 years of executive experience across healthcare, manufacturing, aviation and higher education, with strategic grantmaking focused on home and community-based services. He is quoted in Tombot’s June 2026 financing announcement as the foundation’s president and CEO.

Matthew E Dennison is named as director (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Melanie A Brewer is named as director (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Robert Joyce is named as cfo/cio in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Roland D King is named as director (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Takeshi Goto is Executive Vice President and Director at SBIInvestmentCoLtd. The manager’s corporate directory confirms this exact office asofJune30,2026. The company operates venture-capital funds spanning AI, robotics, healthcare and emerging technologies. His original named portrait is extracted from SBI’s2016annualreport; the currentexecutiveoffice is verified independently in the2026directory.

Thomas R Masters is named as director (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Wade C Root is named as chairman (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

William G Cox Jr. is named as treasurer (2024 filing) in the Lutheran Foundation for Long Term Living’s 2024 Form 990-PF, filed September 19, 2025. Further professional biography and subsequent tenure are not established by this filing.

Yoshitaka Kitao is Representative Director, Chairman and President at SBIInvestmentCoLtd. The manager’s corporate directory confirms this exact office asofJune30,2026. The company operates venture-capital funds spanning AI, robotics, healthcare and emerging technologies.

Apollo Health Ventures current own career biography: Rob is a member of the Advisory Board at apollo.vc Rob Scott has over 30 years of leadership experience in drug discovery and development in the global pharmaceutical and biotechnology industries. As the former Chief Medical Officer and Head of Development at AbbVie, he oversaw successful drug development teams responsible for brands like Norvasc, Lipitor, Repatha, Humira, Skyrizi, and Rinvoq. Prior to AbbVie, he held the positions of Vice President, Global Development TA Head, and Head of Development Design Center at Amgen. During his tenure from 2012 to 2016, Rob served as a member of the US FDA's Cardiovascular and Renal Drug Advisory Committee, establishing strong relationships with senior FDA staff. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Jan is an advisor at Apollo. His career spans venture investing, company building, strategy consulting and basic research in the life sciences. Jan  previously headed commercial activities at the Merck KGaA Innovation Center and was a Managing Director with EMBL Ventures, a Seed and Early-stage VC that was working closely with the EMBL, Europe’s flagship laboratory in the life sciences He’s a trained biochemist with a MSc from Tübingen University and a PhD in molecular genetics from the University of Cambridge, UK as well as a dual MBA degree from ESSEC (Paris) and Mannheim University with distinction Jan is a Class 11 Kauffman Fellow and a recipient of each, a Boehringer Ingelheim PhD, and an Ernst-Schering Post-doctoral Research Fellowship. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Jens is a member of the Advisory Board at apollo.vc He has more than 18 years of biopharma venture capital and company creation experience and 10 years of operational experience in drug discovery and development. Jens previously served as President of GlaxoSmithKline’s corporate venture fund SR One where during his tenure the SR One team invested over 500 million USD and was involved in 18 IPOs such as CRISPR Therapeutics, TP Therapeutics and Principia, as well as 12 M&A transactions. Jens is a Kauffman Fellow, a member of the EU-sponsored Gold Track Expert Council, and a passionate mentor for entrepreneurs and start-up teams in the area of innovative life science and healthcare IT. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: As our Head of Operations & Compliance Kevin has a hands-on approach to Apollo´s internal and external operations. He is involved in different financial, legal, compliance and operational processes of Apollo and its portfolio companies. Before joining Apollo, Kevin was part of the restructuring and insolvency department of Leonhardt Rattunde, a leading insolvency law firm in Germany. During this time he was involved in numerous successful turnarounds, company restructurings and mergers. Kevin studied business and law at the Hogeschool van Amsterdam, Alliance University Bangalore and completed his Master of Laws (LL.M.) at the Berlin School of Economics and Law (HWR). Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Michelle works as a Senior HR manager and recruiter at Apollo and supports Apollo and its portfolio companies in hiring best-in-class talent Michelle has a deep understanding of the HR needs of biotech companies. She holds degrees in Biotechnology and Biomedical Sciences. Michelle started her career at an headhunting agency where she specialized in the pharmaceutical sector and gained experience in recruiting for big pharma Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Marcel is Head of Legal and Tax at Apollo Health Ventures and manages the legal affairs at Apollo and its portfolio companies. He is a fully qualified lawyer in Germany. Before joining Apollo, he worked in the corporate practice of Germany’s leading law firm Noerr where he was involved in numerous private equity and venture capital transactions, including healthcare, biotech and other regulated industries. Marcel holds law degrees from King's College London and Humboldt University of Berlin. Previously, he studied economics, politics and law at the University of Dresden and University of Leiden. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Steven is a Partner and CFO at Apollo Health Ventures since 2018 and oversees Apollo’s and its portfolio companies’ operations and legal affairs. He is actively involved in many of Apollo’s investments and transactions providing advice on deal structures based on his previous experience as a corporate lawyer Steven is a fully qualified lawyer in both Germany and New York, USA and previously worked in the corporate / M&A practice of Germany’s leading law firm Hengeler Mueller where he gained broad experience in the biotech and healthcare industry and was involved in numerous VC deals Steven studied Law at Bucerius Law School in Hamburg, where he also received his PhD in law and completed the Masters of Laws program at Boston University School of Law, where he was awarded a scholarship from the Fulbright commission and the German National Academic Foundation Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Pascale works as an Associate and supports both internal venture creation and external investment opportunities, applying her knowledge in early-stage drug discovery processes She is a molecular biologist by training with a strong focus on neurodegeneration. Pascale obtained her PhD on neuroinflammation in Alzheimer’s disease at the Charité Berlin. She worked for the leading CRO Evotec in the translational neuroscience department. Pascale holds BSc and MSc degrees from the University of Liverpool and King’s College London, has been awarded prizes and fellowships and her work is published in high-ranking scientific journals. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Breakthrough Diagnostics, LLC is an institutional investor in Durin Technologies, the neurodegenerative-disease blood-test business later branded Durin Life Sciences. Durin’s December5,2023 issuer release explicitly identifies this LLC as lead investor in a USD3.5M financing announcement. New Jersey Economic Development Authority investment-tax-credit records independently name the LLC as a Durin investor, and its2025program table locates the applicant in Great Falls, Fairfax County, Virginia. Foundation Venture Capital Group also reports that it sold its Durin equity interest to this LLC, a separate historical secondary transaction with undisclosed price and date. The entity is recorded as a company/institutional investor, rather than presumed to be a public venture manager or LP fund. No official website, authentic entity logo, confirmed public LLC management roster, or outside fund close has been established. Similarly named Breakthrough Diagnostics Inc. businesses—including the Nevada Todos/Amarantus diagnostic subsidiary and an Inc. named in Ric Edelman’s regulatory disclosure—are not merged without exact legal continuity proof. Durin board members and personal investments are kept separate from the LLC’s subscriptions. Tax-credit approval dates and amounts are not treated as company funding-close dates or investor checks.

Apollo Health Ventures current own career biography: Gerd supports Apollo and its portfolio as Venture Partner He has more than 20 years of experience in the pharma and biotech industry R&D and previously led R&D at Jerini AG and OryzonGenomics. Oryzon develops novel therapeutics based on epigenetics Gerd has a broad experience in the development of small molecules, peptides and peptidomimetics covering a wide range of therapeutic areas and therefore can provide highly valuable guidance in shaping R&D Before consulting international biotech companies, he received his PhD in organic chemistry from University of Konstanz Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Chris is a Venture Partner at Apollo and leads severalportfolio companies after incubation Chris co-founded Avogadro Development Corp and Structured BioEquity. He was also the CEO of SmartZyme Biopharma, an OrbiMed portfolio company, where he was in charge of the company’s R&D efforts and an global investor base. In the previous years he supported over $1.5bn in investments and transactions in biotechnology/pharma spanning research, drug program development, combination product development, clinical trial design, and personalized medicine and biomarkers. Chris started his career at Genentech where he worked on the development of several medicines and a number of pipeline assets. He earned his PhD in Molecular and Cellular Pathology at the University of Pittsburgh Medical School of Medicine Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Anne Marije joined Apollo as an investment director in 2024, based in Luxembourg. She is a molecular cell biologist by training, with a focus on targeted therapies in oncology. In her previous role as investment analyst at Forbion, she focused on investments in biotech companies that develop first-in-class therapeutics for inflammatory and fibrotic diseases, as well as in oncology. Her PhD studies focused on aberrant cell cycle regulation and DNA damage signaling in head and neck cancer at the Amsterdam UMC and VU University. She continued her academic tenure in the US where she studied protein interactions in cells undergoing replication stress at the University of Pennsylvania. Subsequently, Anne Marije obtained her own research funding to focus her postdoctoral studies on the development and validation of targeted PROTAC molecules in TP53-mutant cancers at the Thomas Jefferson University in Philadelphia. Anne Marije holds BSc and MSc degrees from the VU University Amsterdam, focused on biomedical sciences and oncology. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check. AnneMarijevanHarten serves on Booster’s current board and is Apollo’s investmentdirector. Own issuer/current manager affiliations preserved; no personal check attribution inferred.

Apollo Health Ventures current own career biography: Florian joined Apollo Health Ventures to expand the health tech and health data vertical. Florian has worked with the Apollo founding team since 2016 and brings more than a decade of experience in venture building, VC, banking, and consulting. He serves on the boards of several portfolio companies and works closely with senior management teams. Florian previously worked in management consulting at Deutsche Bank and studied at the Vienna University of Economics and Business and ESCP Business School. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Apollo Health Ventures current own career biography: Antoine joined Apollo Health Ventures as a Partner in 2025. Previously, he was a Principal at Forbion, where he sourced, led, and managed investments across biotech and therapeutics. He served as Board Director at Calluna Pharma and Mestag Therapeutics, and as Board Observer at Rectify Pharma, Azafaros, Armgo Pharma, Inversago Pharma (acquired by Novo Nordisk), and Dyne Therapeutics (NASDAQ: DYN). He also led due diligence for Versanis Bio, acquired by Eli Lilly. Antoine holds a Ph.D. in Molecular Medicine from Laval University, where he contributed to the discovery of the RANK/RANKL/OPG molecular pathway in skeletal muscle, co-authoring over a dozen publications in muscle physiology and neuromuscular disease. He began his career in life sciences equity research and venture capital, supporting due diligence efforts at BDC’s Healthcare Venture Fund in Canada. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Martina Samwer is Venture Partner at YZR Capital. Martina is an entrepreneur in the healthcare sector and has founded 21Dx GmbH and 22 Ventures GmbH. Before that she worked for more than ten years as a healthcare manager at Schön Clinics and started her career at Bain & Company. She has a background in economics and holds a PhD in law & economics from the University of Hamburg and Columbia University, New York.

Holger Ebersberger is Venture Partner at YZR Capital. Holger studied law at the Friedrich‑Alexander University of Erlangen–Nürnberg, the Johann Wolfgang Goethe University in Frankfurt am Main and the University of Durham. He is a partner at McDermott Will & Emery specialising in M&A and private‑equity transactions. Holger has particular expertise in the digital‑business, TMT, life‑sciences & healthcare, and industrials & manufacturing sectors.

Apollo Health Ventures current own career biography: Ole co-founded Apollo Health Ventures with Nils in 2017 after more than 10 years of investment and operational experience. He supports the Apollo portfolio with hiring best-in-class executives and teams and supports with strategic HR needs as well as team building skills. Ole takes active roles in the portfolio as interim CEO leading portfolio companies to value inflection points Ole is a serial entrepreneur and HR expert, who previously co-founded CareerTeam, a headhunting agency with over 200 employees and offices in 4 countries, placing executives in the tech and life science industry with a focus on building up innovation labs and new businesses Ole finished his PhD with distinction at the University of Cologne and California, Berkeley as the youngest and fastest-finishing postgraduate in his faculty and then joined TruVenturo as a partner in 2011,where he was on the board of several hyper-growth companies Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Urs Keller is Venture Partner at YZR Capital. Urs is a serial investor and entrepreneur with deep expertise in the field of digital platforms. He was active in companies such as billiger.de, web.de, PlanetSports, lokalisten.de, Quandoo, Stylight, Quantumrock Capital and more. Previously, he studied at Karlsruher Institut für Technologie (KIT).

Apollo Health Ventures is an early-stage investment and venture-creation platform focused on biotechnology, data-driven drug discovery and health technology addressing aging and age-related disorders. Its public strategy combines scientist-led company formation with investment in outside ventures; neuroscience exposure includes Scripta Therapeutics, Therini Bio, Bloom Science and Samsara Therapeutics. Apollo Ventures Holding GmbH is the exact Hamburg website operator and historical SEC exempt-reporting adviser, CRD313129/SEC802-121213; the website separately identifies Apollo Health Ventures Management GmbH as its German alternative-investment-fund manager. These entities belong to the published Apollo Health Ventures platform and are qualified rather than conflated with Apollo Global Management, Apollo Projects or Apollo Neuroscience. Founded2017 according to the co-founder biography, it publishes offices in Berlin, Luxembourg and Boston. A final ERA filing datedApril20,2026 means the historical SEC exempt-reporting status is not asserted as a current registration. Its own FundII final closing announcement reports USD180M in2021; company founder shares, asset values and offering targets are not additional cash closes. Its current directory separates investment/operations staff from four advisory-board members.

Elmar H. Willebrand is Senior Advisor at YZR Capital. Elmar Willebrand, by profession a lawyer, joined Asklepios Clinics in October 1993 as head of investments, financing and acquisitions before becoming Group CEO in 1998. During 15 years of his tenure Asklepios grew from 18 facilities with €300 million in sales to over 100 facilities with €2.4 billion in sales and 35 000 employees. Amongst over 90 clinic acquisitions he was in charge of the LBK‑Hamburg transaction, with €750 million the largest European hospital acquisition at that time. In 2008 he founded the AccuMeda Group, which is active in clinic acquisition, turn‑around management, consulting and related investments. He has served as chairman and member of various supervisory boards. His opinion is quoted in leading newspapers.

Michael Bitzer is Senior Advisor at YZR Capital. Entrepreneur and investor / Experienced insurance CEO and board member. From 2006 until July 2019 Dr Michael Bitzer was the CEO of Daman, the National Health Insurance Company, a joint venture between the government of Abu Dhabi and Munich Re. During his time with Daman he also held the role of CEO of Munich Health Daman Holding, was a board member of Saudi Enaya and Daman Qatar, and was a member of the ERGO International Management Committee. Prior to joining Daman he held a number of senior positions for Munich Re in the Middle East and Germany, including responsibility for Munich Re’s health re‑insurance and primary health‑insurance business in the Middle East and Africa. Michael studied medicine and business administration in Germany. He worked in German army hospitals, clinics and held various general staff functions within the army for 16 years. Following his time in the army, he also spent a couple of years in the pharmaceutical industry and consulting.

Georg Grudow Alonso is Investor at YZR Capital. Georg developed strong expertise in technology and finance through his role in Investment Banking at GP Bullhound, where he worked on M&A transactions with high-growth companies. Building on his experience at KPMG in Luxembourg, where he supported cross-border M&A and valuation projects across multiple industries, he developed a strong interest in venture capital, with a particular focus on innovative and health-driven business models. Georg holds a Master’s degree cum laude in Corporate Finance from LUISS Guido Carli in Rome and a double Bachelor’s degree in Business Administration and Law from Universidad Pontificia Comillas (ICADE) in Madrid.

Till Quitzau is Investor at YZR Capital. Till gained valuable full‑time experience as an Associate Consultant at Bain & Company. His passion for venture capital, particularly in the health‑tech sector, was sparked during his VC internship at Redalpine and through his work with the med‑tech start‑up PlusDental. Additionally, Till completed an internship in Investment Banking at Bank of America, where he contributed to several healthcare deals. Till holds a Master’s degree from ESADE in Barcelona and earned his Bachelor’s degree in Business Administration from the University of Mannheim.

Christina Schmidt is Investor at YZR Capital. Christina has been part of the VC and start‑up industry for more than five years. Previously, she gained extensive experience in the VC space by working with B2B software companies at ALSTIN Capital, where she developed a great passion for start‑ups in the health‑tech sector, and by analysing deep‑tech companies at Vito Ventures. In addition, as a key member of the business‑development team at Holidu, Christina acquired B2B sales knowledge in an early‑stage start‑up. Christina has studied Business Administration in Ingolstadt and Cincinnati and International Management in Lisbon and St Gallen.

Markus Feuerecker is Co-Founder & Managing Partner at YZR Capital. Markus Feuerecker has been passionate about scaling healthcare companies throughout his career. As a trained VC, growth & buy‑out private‑equity investor, before co‑founding YZR Capital he held roles such as Vice‑President at DPE Deutsche Private Equity and Senior Investment Manager at EMERAM Capital Partners. Markus studied business administration in Regensburg and Hong Kong and gained experience working for leading banks and consulting firms before starting his investor career.

Reinhard Meier is Co-Founder & Managing Partner at YZR Capital. Reinhard loves supporting European health tech founders on their way to becoming global technology leaders. He has evolved from a practising physician to a tech entrepreneur and investor: He co‑founded telemedicine platform TeleClinic.com, which was sold to a public company in 2020. He has also supported the health‑tech start‑up ecosystem with various investment from his family office. Before that, he worked as Professor of Radiology and Director at a large hospital group after studying medicine and business administration in Munich, Nice/France and San Francisco/USA.

YZR Capital is a founder-led Munich healthcare venture investment firm. Its native imprint identifies the legal manager as YZR Capital GmbH, represented by co-founders and managing partners Reinhard Meier and Markus Feuerecker. The firm backs European healthcare companies from pre-seed through Series B, combining physician, operating, venture-capital and private-equity experience. Its three published investment themes are improving patient care, increasing provider efficiency and innovating healthcare value chains. Current native portfolio examples include dehaze’s AI chronic-disease detection, roclub’s medtech teleoperation, Scan.com’s medical-imaging marketplace, Biorce’s AI-assisted clinical-development technology, deepeye Medical, DeepLife, DaphOS and apoQlar. Its own published team directory names ten investment, advisory and venture-partner team members with substantive biographies and authentic portraits. The firm’s own 2023 disclosure explicitly confirms a second closing of YZR Capital Fund I and welcomes KfW Capital alongside EIF, Bertelsmann Investments and Beiersdorf. A later manager disclosure describes its healthtech-focused EUR100 million Fund I, but the exact final-close date and a directly itemized closed-capital allocation are not established by the retrieved primary materials. The fund is recorded as a verified operating vehicle with its cash amount/date left unspecified rather than treating the original target or a reported platform figure as an exact closing. Scripta Therapeutics’ 2025 seed financing explicitly includes YZR Capital as a participant; the company develops AI- and imaging-supported transcription-factor therapies relevant to neurodegenerative disease. Primary portfolio membership confirms institutional relationships without establishing the date, stage, lead status or individual check of every portfolio investment. YZR’s charitable foundation and affiliated founders’ historical personal investments are distinguished from manager fund cash.

ORI Capital is a Hong Kong and US biotechnology venture investor founded in 2015. It backs early-stage therapeutics, drug-delivery technologies and diagnostics addressing serious diseases, including cancer, cardiovascular and metabolic disorders, and neurodegenerative diseases. The firm combines scientific due diligence with its proprietary ORIZON data and AI research platform to identify investment opportunities and support portfolio companies. Its strategy spans small-molecule drugs, DNA and RNA medicines, cell therapies and synthetic biology. ORI Capital Limited is the published manager identity; its funds and investment subsidiaries are distinct legal vehicles.

PENTAS is a Japanese medical-device company developing and manufacturing devices and planning software for minimally invasive treatment of cerebral aneurysms. Its braided PENTAS Stent supports coil placement inside brain blood vessels, with a dedicated delivery microcatheter and a treatment-planning program that visualizes stent deployment and analyzes blood flow. The stent and accompanying planning program received Japanese approval in August 2022, followed by the microcatheter in February 2023. Its fluid-analysis software component is currently undergoing modification. Based in Kawasaki, the company also develops medical businesses and joined the GENARK group in 2025.

Investment analyst trained in actuarial science, economics and finance.

Healthcare investment professional with prior public-equity research experience.

Biomedical scientist with CRISPR-screening and oncology research experience.

Fund-accounting professional and qualified Hong Kong accountant.

Lawyer with prior private-equity and venture-capital legal experience.

Oncologist specializing in early clinical development of cancer medicines.

Finance executive with RSM, transaction-structuring and tax-advisory experience.

Scientist and founder of Pillar Biosciences and AffyImmune.

Data analyst with quantitative finance and business-intelligence training.

Nobel laureate and scientist specializing in nucleic-acid biology.

Scientist supporting investment-thesis preparation and competitive-landscape research.

Cancer-immunotherapy scientist with translational and cell-therapy research expertise.

Human-resources and operations manager with multinational administrative experience.

Cardiologist and researcher in cardiovascular and metabolic disease.

Molecular-biophysics researcher formerly at Columbia; published as Ben Kong.

Data engineer with computer-science training and prior BNP Paribas experience.

Pathologist with molecular diagnostics and precision-oncology development expertise.

Stem-cell scientist studying cell expansion and therapeutic applications.

Investor-relations professional supporting fundraising and global LP communication.

Healthcare investor and former Goldman Sachs Greater China healthcare banker.

Biotechnology executive and former Flagship Pioneering operating partner.

Marianne Mertens is listed by Scripta Therapeutics as Board Representative, Apollo Health Ventures (director/observer unspecified). Current published affiliation reviewed October7,2026; exact appointment day is not established. Apollo Health Ventures current own career biography: Marianne joined Apollo as a Partner in 2021 and represents the fund on the boards of HAYA Therapeutics, Auron Therapeutics, and Cleara Therapeutics. She also serves as CEO and Board Director at Booster Therapeutics and led Apollo’s investment in Therini Bio. She has more than ten years of experience in the life sciences industry, spanning venture investing, strategy consulting, and research. She previously led investments in several life sciences companies, including Cardior Therapeutics (acquired by Novo Nordisk), Confo Therapeutics (licensing agreement with Eli Lilly), and ImCheck Therapeutics. She held roles as a Principal at Wellington Partners and as an Investment Manager at HTGF, representing investors at the board level. Before joining the life sciences team at High-Tech Gründerfonds, she worked as a management consultant, supporting pharmaceutical and medical technology companies. Marianne obtained both her Bachelor's and Master's degrees with distinction in Biotechnology from RWTH Aachen University and The Scripps Research Institute. She conducted her PhD research on molecular imaging of cardiac regenerative medicines, and her work has been recognized with several awards. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check. Current Booster own roster identifies MarianneE.Mertens as a board member representingApollo. The2024issuer release also names managingdirector; an olderApollo own bio saysCEO, but a current standaloneCEO appointment is not established by the presentIssuerdirectory. Existing Scripta board role/originalportrait preserved.

Raymond Barlow is listed by Scripta Therapeutics as Non-Executive Director. Current published affiliation reviewed October7,2026; exact appointment day is not established.

Noel Buckley is listed by Scripta Therapeutics as Academic Co-Founder. Current published affiliation reviewed October7,2026; exact appointment day is not established.

John Blackwood is listed by Scripta Therapeutics as Vice President of Biology. Current published affiliation reviewed October7,2026; exact appointment day is not established.

Andy Walker is listed by Scripta Therapeutics as Vice President of Bioinformatics. Current published affiliation reviewed October7,2026; exact appointment day is not established.

Jerry Huang is listed by Scripta Therapeutics as Vice President of Machine Learning. Current published affiliation reviewed October7,2026; exact appointment day is not established.

Brian Sanders is Gates Ventures’ manager of technology programs, as identified in Kontent.ai’s current first-party customer testimonial. His own professional profile records technical project-management and software/UX collaboration experience, with computer science and mathematics minors at Pacific Lutheran University. The testimonial concerns content-management technology and is not evidence of an equity investment in the supplier.

Martin Topper is a publicly identified Gates Ventures professional. His public professional profile identifies Gates Ventures affiliation, New York CPA credentials and study at Brooklyn College. It also describes nonprofit board/treasurer service with Raising Multiples. The reviewed primary source does not publish a Gates Ventures CFO title.

Naomi Zukor is a publicly identified Gates Ventures professional. Her public professional profile identifies Gates Ventures affiliation and a communications/public-relations background, with study at Willamette University and a 2014 PR News Rising Star recognition. The source does not establish a precise office title.

Kirk McGough is a publicly identified Gates Ventures professional. His public professional profile identifies Gates Ventures affiliation, construction-management experience, Certified Construction Manager certification and study at the University of Washington. The source does not establish a precise office title.

Chris Presley is a publicly identified Gates Ventures professional. His public professional profile identifies Gates Ventures affiliation and a close-protection leadership role. His background includes Ball State University.

Kristina Malzbender was identified as associate director in Health & Life Sciences at Gates Ventures in her June 2024 StartUp Health interview. She discussed Alzheimer’s biomarkers, diagnostics and clinical trials, the Diagnostics Accelerator partnership and a prior consulting background. The affiliation is source-dated; the reviewed primary materials do not establish her current term or a departure date.

Gates Ventures’ own public company profile identifies Pia Dierking as a team member. Her public professional profile records study at the University of Colorado Boulder Leeds School of Business. Bill Gates’ published podcast credits identify her as a producer, providing dated evidence of communications work without establishing her current job title.

Farhad Imam is a physician-scientist whose work in the Gates ecosystem included drugs, devices and diagnostics for global health and Alzheimer’s disease, and the GRIP research platform. His own 2026 announcement states that he has left that chapter and taken a strategic advisory role at the OpenAI Foundation. The GRIP directory’s older Gates affiliation is retained as historical context and is not treated as a current office position.

Aishwarya Sukumar, known publicly as Aishu, described leading Gates Ventures Alzheimer’s efforts and the Diagnostics Accelerator partnership with ADDF in her June 2024 StartUp Health interview. Her background includes research in oncology and neurodegeneration, a translational fellowship at Harvard’s Wyss Institute and healthcare startup/commercialization work. A published 2026 CTAD preliminary program confirms her Gates Ventures affiliation; the planned conference presentation is not represented as completed.

Matthew Clement is identified by Yale’s October 2025 announcement as a director of Health & Life Sciences at Gates Ventures and director of scientific strategy at the Alzheimer’s Disease Data Initiative. Current Alzheimer Europe and ADDI materials describe his partnerships and scientific-strategy remit. His publicly documented research partnerships concern aging, Alzheimer’s disease and the responsible use of research data.

Christina Bowles announced joining Gates Ventures as senior program manager in Health & Life Sciences in 2026. Her stated work supports Alzheimer’s data initiatives and equitable access to healthcare innovation. Her earlier professional background includes nonprofit and community-led health development, with research on community health workers in Sierra Leone.

Ramasubramanian Ramani, also publicly known as Rama Ramani, announced joining Gates Ventures’ Health & Life Sciences team in 2026 after nearly two decades at Microsoft. His stated remit is chief technology and product officer for the Alzheimer’s Disease Data Initiative product suite. The current ADDI directory publishes the same abbreviated name and product/technology title; it does not establish a separate corporate investment vehicle.

Gates Ventures’ own public company profile identifies Tom Stocky as a team member. His public professional profile and GRIP directory confirm technical advisory work in biomedical research. His earlier leadership includes Insitro’s lab and data platform, Facebook search and profile products, the Chan Zuckerberg Initiative learning platform and Google. The reviewed primary sources do not publish his precise Gates Ventures job title.

Gregory Moore is a physician and engineer serving as a senior adviser to Gates Ventures. Fortive’s current board biography confirms this affiliation, his Microsoft health and life-sciences leadership from 2019 to 2023 and earlier Google Cloud healthcare leadership. He is board-certified in diagnostic radiology, neuroradiology and clinical informatics, and also contributes to GRIP’s technical advisory group.

Larry Cohen is CEO of Gates Ventures, the private office established by Bill Gates in September 2008, and a Khan Academy board member. Previously he was Microsoft corporate vice president of marketing, having joined Microsoft in 1995 to work on its early online businesses. Earlier he held product-management positions at Apple/Claris and Collabra Software, which was acquired by Netscape.

Peter Tam is identified as a director in Tombot’s primary SEC FormC filed October31,2024, signing as Director on October30. The current own story page retains the older board-observer title; both disclosures are qualified rather than treating an undated website as superior to the dated statutory filing. Exact appointment/transition day remains unknown. His background includes product design, manufacturing control and medical instrumentation, with electrical-engineering bachelor’s and master’s degrees from California State University. Experience with FDA/ISO-regulated products does not establish Tombot FDA clearance or a personal investment.

Jay Goss is a published Tombot director, with appointment from2021 reported in the SEC2022 filing. The current issuer biography identifies him as a general partner of Wavemaker Three-Sixty Health. His business-building career includes Disney, Reed Elsevier, Summa and UCLA. The genuine issuer headshot and corporate-director affiliation are distinct from any investment made by the institutional manager; no personal cash investment is inferred. General partner and early-stage company operator with experience in commercialization, fundraising and product development. Earlier corporate-development roles included Disney/ESPN, Reed Elsevier and Summa Group. Holds USC Marshall MBA focused on entrepreneurship and UCLA economics/business bachelor’s. Existing Tombot director biography and portrait preserved.

Chris Winkle is listed in Caduceus Capital Partners’ current official directory as Executive Venture Partner. His operating experience spans acute care, senior living and diagnostic imaging. He previously led Sunrise Senior Living and MedQuest.

Publicly listed OMVC advisor with an authentic own-manager portrait. His own professional profile describes work leading a moonshot team related to supply-chain resiliency, efficiency and sustainability atX,theMoonshotFactory. No unverified investment tickets, personal portfolio or precise outside appointment date is attributed toOMVC.

Jesse Schorz (legal name Jesse M. Schorz) is Tombot’s co-founder and current COO, with service from2018 reported in the SEC2022 filing. His own biography describes more than20 years of management and earlier engineering leadership at DiscoverReady. His responsibilities include operations, supply chain, logistics and information technology. No personal investment is inferred from employment or founder status.

Sue Tyler is listed in Caduceus Capital Partners’ current official directory as Venture Partner. She previously held financial and operating executive roles at Medical Mutual of Ohio and now supports early-stage businesses through investing, mentoring and board work.

Publicly listed OMVC advisor, with an authentic named own-manager portrait. His historical2021 Persistent Systems company release identifies him as Chief Strategy Officer, and his earlier authored banking paper describes innovation and research leadership atWellsFargo. These dated outside roles establish professional background and do not prove current2026 employment at either corporation.

Hank Schorz (legal name Henry P. Schorz) is Tombot’s current co-founder and chief technology officer, identified by the issuer and SEC filing as serving from2017. His own biography describes more than40 years in technology and earlier co-founding and executive leadership of ACT Litigation Services. He oversees the robotic companion’s technology; current manager or founder positions do not imply a personal cash check.

Publicly listed OMVC advisor. An issuer’s2025 SEC filing independently identifies him as managing member of2LAdvisors and a venture partner atTuesdayCapital, connecting his investment experience to digital infrastructure. Earlier career history includes senior leveraged-finance work atUBS,JPMorgan andDeutscheBank. His own manager portrait and linked professional identity support the exact person match; no personal investments are assigned toOMVC.

Eric Thrailkill is listed in Caduceus Capital Partners’ current official directory as Venture Partner. He founded Allee Advisory Services after CIO roles at PhyCor, America Service Group and AMSURG. His expertise includes healthcare analytics, partnerships and revenue-cycle strategy.

Tom Stevens (legal name Thomas Edward Stevens) is Tombot’s co-founder and CEO. His current own biography describes more than30 years in technology leadership, and the SEC2022 filing names him CEO, chief product officer and chairman since2017. Stanford MS Management2017 and UCLA BA PoliticalScience2016 are disclosed in that filing. This record is distinct from the unrelated existing ThomasStevens investment executive. Historical additional officer titles are not automatically asserted current; founder affiliation does not establish a personal cash investment.

Tombot, Inc. is a Delaware corporation formed October13,2017 and based in Santa Clarita, California, developing robotic companion animals for people unable to safely or practically care for a live pet. Its first product Jennie is an autonomous, lifelike robotic Labrador puppy, designed with Jim Henson’s Creature Shop. Touch and voice-responsive behaviours, motion and sound provide companionship and comfort; published intended users include people living with dementia or mild cognitive impairment, anxiety, loneliness, autism and PTSD. This is companion robotics and assistive technology, not a demonstrated diagnostic AI system or a cure for those conditions. The company’s current public team names co-founders Tom Stevens (CEO), Hank Schorz (CTO) and Jesse Schorz (COO), director Jay Goss and Peter Tam (website observer; dated October2024 SEC director). Legal names Thomas Edward Stevens, Henry P. Schorz and Jesse M. Schorz are corroborated by SEC filings; unrelated people named Thomas Stevens are not merged. The June25,2026 issuer release reported a successful USD7million Series A3 close, following a separate USD6.1million Series A announced June12,2025. Its reported 23,000 pre-order/waitlist customers and planned Fall2026 launch are company statements about demand and plans, not verified completed shipments or revenue. Its investor website describes FDA medical-device status and reimbursement as anticipated future milestones. No FDA clearance, approved indication, independently established clinical benefit or reimbursement is asserted. SEC and platform crowdfunding disclosures distinguish completed securities sales from commitments and maximum offering targets. Exact cents unsupported by the database are preserved in source evidence with NULL amount. PicMii’s reported closed USD412589 campaign is retained as a qualified component disclosure with NULL standalone amount because overlap with the larger2025 financing has not been independently resolved; it must not be summed as extra capital. Historical cumulative investor amounts as of September2022 are separate relationships, not an additional USD4.6million round. Annual financial-statement cash flows and noncash SAFE conversions are not invented priced rounds.

Publicly listed OMVC venture partner with an authentic manager portrait. The2026 CRE-UP program run by Brinc Korea independently identifies her OMVC venture-partner affiliation and describes earlier director experience at Techstars and managing-director experience at JPMorgan. Those prior roles are treated as historical, not current employment.

OMVC advisor and founder of Format One, advising founders, funds, institutional investors and companies on strategy, product, commercialization and fundraising. Previously a partner at500Startups, an entrepreneur in residence atExpa, founder of ReTargeter and a business-development leader atYahoo. Holds an electrical engineering and computer science degree fromUC Berkeley. His personal investments in AI and deep-technology businesses are distinct from institutional OMVC investments.

Jeff Sturman is listed in Caduceus Capital Partners’ current official directory as Executive Venture Partner. He is associated with WittKieffer executive-search and IT advisory leadership and brings operational experience in healthcare technology transformation.

Kirk Stanley is listed in Caduceus Capital Partners’ current official directory as Venture Partner. His background includes health-plan operations, value-based care and technology-enabled healthcare services, including INSPIRIS and PopHealthCare. The directory lists Tango while the longer biography retains PopHealthCare; that external-employer discrepancy is not resolved by inventing another role.

Al Smith is listed in Caduceus Capital Partners’ current official directory as Venture Partner. He is associated with LifePoint Health information-technology leadership and brings experience in healthcare systems, insurance and technology consulting.

OMVC Communications and Brand Manager, responsible for messaging, thought leadership, newsletters, media relations, investor communications and events. Previously worked as a financial journalist for eight years, covering China’s economy and capital markets, then produced events and marketing content for an expert network and MSCI. Her own team biography describes a Hong Kong background and study in the UK.

OMVC’s current official team directory identifies Mohamed Zaki as Technology Director and publishes his authentic named portrait and professional-profile link. The site has no completed long-form biography for him; past employers, education, achievements and an exact appointment date are not independently established. This technology-investment professional is distinct from same-name Egyptian political or medical figures.

John D. Simon is listed in Caduceus Capital Partners’ current official directory as Executive Venture Partner. He brings healthcare business-development, sales and strategy experience, including leadership at Optum and provider consulting work.

OMVC, short for OM Venture Capital, is the early-stage manager operating omvc.co and the2025 rebrand of Vectr Fintech Partners. Founder announcements explicitly retain the partnership with the separate Vectr Ventures organization; this change does not rename all Vectr Ventures or transfer its earlier biotechnology investment history. OMVC invests in seed and Series A businesses across North America, Asia-Pacific and the Middle East, combining fintech with frontier innovation and climate/resource technology. Its own current portfolio includes AI-agent company Wand, vector-infrastructure company Superlinked, NLP platform Accern and AI market-making company Air Trading. The current team directory publishes six core people, three venture partners and six external advisors, all with authentic named portraits. Ben Hoxie is now Principal and Marc Palet Associate; older Vectr analyst titles are historical. The site’s privacy policy identifies OMVC Ventures Limited as its operator. The official Hawaii HTDC investment memorandum identifies OM Venture Capital LLC as manager of OMVC Hawaii Fund I LLC. These are qualified operating/management entities within the public OMVC brand, not an asserted merger into a single legal corporation. Its own history and founder posts place the inaugural VFP fund in2018, while HTDC’s memorandum uses2019 as FundI vintage; exact legal incorporation date is not assumed. Cayman CIMA confirms Vectr Fintech Partners LP and Vectr Fintech II LP legal fund registrations. SEC’s2022 FormD records only partialUSD650,000 sold in FundII; a later official December2025 HTDC memorandum explicitly statesUSD38M has already closed in that fund. The actual final close day is unpublished. OMVC FundIII’sUSD100M overview is a fundraising target, while Hawaii FundI’sUSD6M plan and conditionalUSD3M state allocation are not independently verified total closed cash. The current HI-CAP program confirms Hawaii FundI has received investment but gives no exact draw, fullfund amount or close date. Portfolio-company capital raised, AUM, targets, network advisors’ personal investments and related Vectr funds are not treated as new manager cash. The portfolio template contains an exit element on every item; this is not treated as proof all companies are exited. Exact company stages require transaction-level primary sources.

Amy Sikes is listed in Caduceus Capital Partners’ current official directory as Director of Client Services, Caduceus ADVISORY. She manages advisory client engagements involving healthcare operations, revenue-cycle improvement and digital-health or AI solution implementation.

Jessica Rudish is listed in Caduceus Capital Partners’ current official directory as Venture Partner. She leads healthcare executive-search and interim-management work at Rudish Health, following healthcare strategy and operations consulting at Deloitte.

Roy Sailor is listed in Caduceus Capital Partners’ current official directory as Venture Partner. His healthcare technology and business-development experience includes Optum, CSC and Perot Systems. The current directory associates him with Upswing Health.

Craig Richardville is listed in Caduceus Capital Partners’ current official directory as Venture Partner. He is associated with UF Health digital and information leadership and previously served in CIO roles at Intermountain and SCL Health.

Larry Neiterman is listed in Caduceus Capital Partners’ current official directory as Executive Venture Partner. He formerly held senior operating and finance leadership roles at Deloitte Consulting and now advises early digital-health businesses as a venture partner.

Steven Packer is listed in Caduceus Capital Partners’ current official directory as Executive Venture Partner. A physician and former long-serving CEO of Montage Health, he brings experience leading integrated healthcare delivery systems and boards.

Mimi McNabb is listed in Caduceus Capital Partners’ current official directory as Consultant, Caduceus ADVISORY. She researches digital-health solutions and supports strategic recommendations, financial analysis and technology evaluation within the affiliated advisory service.

Jon Kaplan is listed in Caduceus Capital Partners’ current official directory as Executive Venture Partner. He works in healthcare strategy at Boston Consulting Group, including payer and services businesses, payment models and healthcare consumer markets.

Meera Kanhouwa is listed in Caduceus Capital Partners’ current official directory as Venture Partner. She has developed and commercialized healthcare technology, including Azyxxi and Microsoft Amalga, and is associated with AcumenHIT.ai.

Judson Ivy is listed in Caduceus Capital Partners’ current official directory as Venture Partner. He founded Ensemble Health Partners in2014 after a career in hospital revenue-cycle operations. His expertise includes provider revenue management and operational improvement.

Phil Hertik is listed in Caduceus Capital Partners’ current official directory as Venture Partner. Philip Hertik is a retired founder and executive of Windsor Health Group, whose healthcare insurance business was acquired by Munich Re.

Gracie Francis is listed in Caduceus Capital Partners’ current official directory as Principal, Caduceus TALENT. She recruits executives and other candidates for venture-backed healthcare companies through the affiliated talent service; her earlier work included Alvarez Search.

Jess Haraden is listed in Caduceus Capital Partners’ current official directory as Associate, Caduceus TALENT. She supports executive-search delivery, candidate outreach, scheduling and recruitment pipelines at the affiliated talent service.

C. Brian Fox is listed in Caduceus Capital Partners’ current official directory as Venture Partner. Brian Fox founded electronic audit-confirmation company Confirmation, which was acquired by Thomson Reuters in2019. He has worked on fintech products and accounting fraud prevention.

Natalie Edwards is listed in Caduceus Capital Partners’ current official directory as Vice President of Client Services, Caduceus ADVISORY. Her experience covers healthcare technology consulting, operations and life sciences. In the affiliated advisory service she manages delivery of innovation and transformation programs.

Carrie Deaton is listed in Caduceus Capital Partners’ current official directory as Director of Investor Relations, Caduceus Capital Partners. She manages investor communications and related internal systems, drawing on project-management and healthcare IT experience.

Kevin Conroy is listed in Caduceus Capital Partners’ current official directory as Director, Finance & Accounting. He supports accounting, financial forecasts, cash-flow planning and portfolio reporting at the investment platform.

Martin J. Bonick is listed in Caduceus Capital Partners’ current official directory as Venture Partner. Marty Bonick formerly led Ardent Health Services. His background includes managing hospital systems and expanding healthcare businesses through quality improvement and operational innovation.

Bill Brown is listed in Caduceus Capital Partners’ current official directory as Venture Partner. He is a healthcare-business operator associated with Genomind. His background includes physician-practice management, growth acceleration and company exits.

Bo Bartholomew is listed in Caduceus Capital Partners’ current official directory as Venture Partner. Also known as Samuel Bo Bartholomew, he leads EvidenceCare and previously founded PharmMD, later AdhereHealth. His experience includes clinical technology, medication management and hospital operations.

Mitch Morris is listed in Caduceus Capital Partners’ current official directory as Managing Principal, Caduceus LAUNCH. A physician and healthcare transformation executive, he previously held leadership positions at Optum, Deloitte and MD Anderson. His current role directs the affiliated accelerator.

Lindsay Valdez is listed in Caduceus Capital Partners’ current official directory as Chief Financial & Operating Officer. She manages the platform’s finance, business operations, budgets and service-line processes, and works with investors and portfolio leaders.

Peter Micca is listed in Caduceus Capital Partners’ current official directory as Managing Partner. His professional-services experience spans healthcare, technology and life sciences, including growth businesses backed by venture and private equity. He supports strategic relationships and healthcare innovation.

Adam Bauer is listed in Caduceus Capital Partners’ current official directory as Managing Partner. He has worked in healthcare transformation at Deloitte, EY and NTT Data, and joined the managing-partner team in2025. His current biography also identifies him as CEO of the affiliated ADVISORY service.

Russ Rudish is listed in Caduceus Capital Partners’ current official directory as Managing Partner. He founded Rudish Health after leading professional-services businesses serving healthcare organizations. His work spans executive recruitment and healthcare advisory services.

Ryan McKindles is listed in Caduceus Capital Partners’ current official directory as Managing Partner. His background combines healthcare technology consulting, entrepreneurship and legal work. He previously co-founded and led Healthrise and now helps direct fundraising and investment execution.

Scott Kolesar is listed in Caduceus Capital Partners’ current official directory as Co-Founder and Chairman. He co-founded the platform in2020 after digital-health operations, consulting and venture work, including Jumpstart Capital. SEC filings identify him as Michael Scott Kolesar. His current biography names chairman of Caduceus Capital Partners II LLC.

Dave Vreeland is listed in Caduceus Capital Partners’ current official directory as Senior Managing Partner. He oversees early-stage digital-health investing and serves on portfolio company boards. He co-founded the platform in2020; SEC filings identify him legally as Frederick David Vreeland.

Caduceus Capital Partners is a Nashville-based venture-capital platform founded in2020 by Scott Kolesar and Dave Vreeland. It invests in early-stage US digital-health businesses that serve healthcare providers and payers, including clinical decision support, AI revenue-cycle automation, voice agents and companion robotics. Its investment arm Caduceus CAPITAL works alongside the affiliated Caduceus TALENT recruiting service, Caduceus LAUNCH pre-seed accelerator and Caduceus ADVISORY consulting service. The public directory distinguishes managing partners, operating staff, venture partners and service-line specialists. FundI is a Delaware limited partnership with Caduceus Capital Partners GP LLC as general partner and Caduceus Capital Partners LLC as sole manager of the GP. FundII uses separate GP II LLC and manager II LLC entities under the same public platform. These vehicles are not collapsed into one legal subscriber or allocated to every portfolio check. FundI announced a USD29M close inJuly2023, while the immediately preceding SEC filing reported28,876,921USD sold; the announced size is reported rounded, not an inferred exact LP commitment. FundII’s initial50MUSD target with zero sold is excluded from closed capital. This2020platform is distinct from historical OrbiMed Caduceus funds and the former Lancet Capital name.

Ascense Medical is a Vienna-based medical-device developer working on elastic vascular and endovascular grafts for aortic disease. Its Complion material platform is designed to mimic the elasticity of a healthy aorta and preserve its Windkessel function: absorbing pressure peaks and maintaining more continuous blood flow. The company is developing knitted polymer grafts with a polyurethane coating for aortic dissection and other aortic repair applications, with the aim of reducing complications associated with conventional stiff grafts. Its current published materials describe product development; a historical target for a European launch in 2026–2027 is a development forecast, rather than proof of regulatory approval or commercial availability.

Cardiovascular surgeon and researcher specializing in open and endovascular treatment of aortic disease. Listed in Ascense Medical’s founding team and current company leadership and shareholder directory.

Regulatory and quality consultant with more than 26 years of experience in medical devices, biologics and pharmaceuticals. Her company biography lists prior work with Zimmer Biomet, Medtronic and TÜV SÜD America and leadership of MFORCE3 Quality Concepts.

Medical-device engineer and executive with more than 30 years of experience in product development, including cardiovascular and neurovascular devices. His career includes DePuy Orthopedics, Cordis and Medtronic and early-stage medical-device companies.

Cardiac surgeon specializing in aortic therapies and co-founder of Ascense Medical. His current company biography identifies him as chief physician for cardiac, pulmonary and vascular surgery at Westpfalz Clinic in 2026.

Medical-device engineer with experience developing catheters, hearing devices and sensors and transitioning Class II and III products under European medical-device regulation. Leads development of Ascense Medical’s Complion material platform.

Nicky Lu is a semiconductor entrepreneur and technical adviser identified in Goodman Capital’s archived primary team directory. The historical biography describes founding and leading Etron Technology, earlier IBM research and engineering, Stanford graduate degrees and National Taiwan University undergraduate studies. His Goodman advisory affiliation is last-published historical; current role and exact service dates are not verified.

Alec Mahmood was identified as VSP Global’s chief administration officer and chief financial officer in the company’s December 2021 leadership announcement. This record preserves that historical corporate affiliation following the VSP Vision brand change. A later change to chief operating officer and a newer finance appointment appeared in secondary listings but were not primary-confirmed, so neither an ongoing 2026 CFO role nor those later titles is asserted.

Wendy Hauteman is VSP Vision’s chief marketing officer, explicitly quoted in its March 2022 rebrand announcement and named again in the group’s 2025 impact report published in 2026. Her published work includes the VSP Vision visual identity and stakeholder-facing corporate brand strategy. The impact report also describes her volunteering with the Eyes of Hope mobile clinic. These corporate and charitable activities do not establish a personal investment check.

Christian Bachmann is listed in the official Austrian company register as Brightmind.AI’s insolvency administrator, registered July3,2025. This is a legal-administration role, not an employee or investment affiliation.

Christian Windischberger advises Brightmind.AI on science and engineering. His published biography describes MR physics, closed-loop technologies, TMS and stimulation-coil engineering at the Medical University of Vienna.

Florian Lerchbammer-Kreith co-founded Brightmind.AI and is published as an advising co-founder. The company explicitly says he is no longer operationally involved. His background includes medtech, private-equity and corporate-finance consulting at BCG and an INSEAD MBA.

Gregor Brössner advises Brightmind.AI on clinical migraine research. His published biography describes neurology, headache medicine and pain-management expertise, including leadership of a headache clinic in Innsbruck and experience conducting headache trials.

Iain Strickland advises Brightmind.AI on neuromodulation and commercialization. With doctoral training in neuroscience, his published biography describes introducing a headache-neuromodulation device into UK clinical practice and securing reimbursement.

Ingo Schroeter advises Brightmind.AI on strategy and product. His published biography describes technology and medtech consulting at BCG and strategy and partnering responsibilities at Philips, including IP and licensing work.

Jennifer Berman advises Brightmind.AI on migraine commercialization. Her biography describes pharmaceutical and neuromodulation product-launch experience, including migraine programs at Impel Pharmaceuticals, Novartis and electroCore.

Johannes Frank is named in the official Austrian register as a Brightmind.AI shareholder, registered November28,2023. The register does not establish an individual cash ticket, investment round or detailed professional biography.

Peter McAllister advises Brightmind.AI on neurology and headache medicine. His published biography describes clinical migraine research and leadership at the New England Institute for Neurology and Headache and related clinical-research organizations.

Rand Almajidy is Brightmind.AI’s published medical engineer. She has doctoral training in medical engineering, including brain-computer interfaces, EEG signal processing, neuroelectronic systems and machine learning.

Shivang Joshi advises Brightmind.AI on neurology and headache medicine. His biography describes headache research and clinical leadership at Community Neuroscience Services, following neurology training at Beth Israel and neuroscience teaching at Harvard.

Stan Woods is published as Brightmind.AI’s consulting director for engineering. He previously led development and operations at eNeura, including mobile TMS device development and regulatory work. eNeura’s clearance is not proof of Brightmind device approval.

Tibor Zechmeister advises Brightmind.AI on regulatory affairs, quality-management systems and clinical-trial planning, drawing on prior founder experience described in his company biography.

Uzair Rashid is Brightmind.AI’s published chief commercial officer. His biography describes healthcare technology and commercial work at Cardinal Health, Pure Health, CVS Health and Blue Cross Blue Shield of Massachusetts, and data-science studies at Harvard.

Brightmind.AI GmbH is an Austrian neurotechnology company incorporated on September 16, 2022, developing personalized, non-invasive transcranial magnetic stimulation combined with EEG feedback and machine learning. Its initial research focus is migraine prevention, with professional-use and home-use device development described on its website; broader neurological applications are research ambitions. Its published roadmap does not establish regulatory approval, completed clinical efficacy trials or a commercial launch. The legal entity is registered in Vienna under FN 588896z, VAT ATU78525678. The official Austrian register records an insolvency publication in July 2025 and insolvency administrator Dr. Christian Bachmann, while continuing to list the entity as registered. The website’s leadership and adviser roster is documented as published affiliations; continuing operational tenure after the insolvency is unverified. ISTcube, now XISTA Science Ventures, announced an undisclosed foundational pre-seed investment in September 2022. The same primary announcement describes an EUR800,000 aws Seed award; full cash disbursement is not established. The company separately reports EUR3.3M cumulative funding including EUR2.4M combined non-dilutive support from aws and FFG, without dated individual allocations. Its statement that it was selected for a University of Oxford investment is not proof of a completed financing or a specific Oxford legal vehicle.

Gregor Kowarik is Brightmind.AI’s published co-founder and chief technology officer. His background includes electrical engineering, a doctorate in technical physics, medical-device engineering and development leadership at MedAustron, plus prior Siemens and Austrian Institute of Technology work.

Luca Ticini is Brightmind.AI’s published chief scientific officer, with doctoral training in neural and behavioural sciences and cognitive-neuroscience research involving TMS, stroke recovery and motor-system function.

René Gilvert is Brightmind.AI’s published co-founder and CEO and the registered managing director since April5,2024. His company biography describes commercial leadership in digital medicines, neurodegeneration and pharmaceutical marketing at Novartis and Takeda, and experience founding a neurotechnology business.

Tamara Gerbert founded Brightmind.AI and is published as VP of Strategy and Director of Neuroscience. Her research background includes closed-loop non-invasive brain stimulation, EEG and MRI analysis, and AI methods for neurological data. She studied neuroengineering at Imperial College London and at King’s College London.

Goodman Capital is the Singapore-based private investment firm founded in 2013 by Jeffrey Lu and Daphne Teo, identified on its original website as Goodman Capital Limited. Its archived primary mandate describes seeding, investing in and incubating early-stage technology and biotechnology companies across Asia and the United States, alongside real estate and occasional consumer investments. The firm invested its principals’ and their families’ capital directly and worked with co-investors, combining capital with strategic and operating support. Archived primary team biographies identify Jeffrey Lu as co-founder, Daphne Teo as co-founder and managing director, and Timothy Lu and Nicky Lu as advisers. These are historical last-published affiliations; a current operating roster or continued activity has not been independently verified because the original website is unavailable. Its historical portfolio includes Engine Biosciences and other biotechnology and technology businesses. This Singapore firm is distinct from the New York real estate debt manager Goodman Capital LLC, Goodman Capital Finance, Australian Goodman Group and UK Tech Nomads’ former name. Its own-capital model does not establish a third-party LP fund close; no independently verified closed private fund amount is claimed.

Earnie Franklin was explicitly named VSP Global chief operating officer in the company’s December 2021 leadership announcement. The group rebranded VSP Vision in 2022. This historical affiliation is retained with its source date; no later role, departure date, current continuation or personal investment is inferred. A detailed native career biography and authentic portrait were not verified.

Chris Enslin was identified as president of Eyefinity in VSP Global’s December 2021 leadership announcement. Eyefinity supplies optometric practice software within the corporate group now called VSP Vision. This record preserves the dated primary affiliation without asserting that he remains in this role in October 2026. Detailed primary biography and an authentic named portrait remain unverified.

Indar Chaudhuri was identified as president of VSP Optics in VSP Global’s December 2021 executive-roster announcement. VSP Optics is an operating business within the group now branded VSP Vision. This is a historical last-confirmed affiliation; no comprehensive current directory, exact service dates, current continuation, detailed native biography or authentic portrait was verified.

Matt Wickham, OD, was named VSP Vision board chair in January 2024 for a two-year term, having previously served as vice chair and on the board for seven years. He graduated with honors from the University of Missouri–St. Louis College of Optometry in 1993, spent seventeen years at TLC Laser Eye Centers, and co-founded Regional Eyecare Associates with Lisa Mackey in 2005. The dated appointment does not establish an automatic term extension into October 2026.

Greg Hare is identified as president of Visionworks in VSP Vision’s October 2024 network-leadership announcement, retaining that operating-business role and reporting to newly appointed chief network officer Jeff Koziel. The public primary source establishes this group leadership affiliation. A detailed primary career biography, authentic named portrait and continuation after that dated confirmation were not verified.

Kristi Cappelletti-Matthews is VSP Vision’s chief human resources officer, explicitly identified in the company’s September 2024 announcement of her fourth consecutive N2Growth Top CHRO recognition. The issuer describes her work in leadership development, workforce culture, operational efficiency, digital transformation and employee well-being. Her affiliation is qualified to this last-confirmed primary disclosure rather than a guessed October 2026 roster.

Jeff Koziel was appointed VSP Vision chief network officer in October 2024, overseeing network strategy and associated units including VSP Ventures, onsite clinics, Eyeconic and Visionworks. He began as a Walgreens pharmacist in Chicago and held progressively senior roles over twenty-five years, including senior vice president overseeing healthcare and retail operations across more than 9,000 locations. He most recently served as president of Dental Care Alliance, supporting 400 practices in 24 states. His VSP role is qualified to the issuer’s published appointment.

Kathleen Steele became president of VSP Ventures in January 2023 and was explicitly confirmed in that position in VSP’s October 2024 network-leadership announcement. VSP Ventures offers care-focused practice-transition options for optometrists; it is not established as an external LP venture fund. Steele previously led Pearle Vision as senior vice president and general manager and held Luxottica leadership roles in operations, vision-care strategy, innovation and commercialization.

Vertex Ventures Japan is a Tokyo venture-capital firm investing in early-stage Japanese technology companies in deep technology, artificial intelligence, digital transformation and the creator economy. It provides capital and hands-on support for business development, strategic partnerships and international expansion, connecting founders with corporate and investment networks across Asia, the United States and Israel. It operates as an independent Japan investment team within the Vertex network.

Leads the investment committee at Vertex Ventures Japan and is group president and CEO of Vertex Holdings. He co-founded internet communications company MediaRing and previously held senior positions in medical devices, venture capital and industrial companies.

Supports enterprise partnerships and international growth at Vertex Ventures Japan. His experience includes senior roles at International Enterprise Singapore and the Singapore Economic Development Board, developing startup investment programs and international business ecosystems.

Advises Vertex Ventures Japan and serves as president and CEO of Warehouse TERRADA. He founded IT infrastructure business Bit-isle, led its public listing and subsequent acquisition by Equinix, and supports startups through the Creation Camp TENNOZ incubation program.

Invests in and supports startups from early stage through growth across AI, SaaS, digital transformation and entertainment. His experience includes business development, founding companies and investing at Bonds Investment Group, whose fund is currently in its realization phase.

Invests in seed and early-stage businesses based on physics and chemistry, including semiconductors, advanced materials, biotechnology and regenerative medicine. His background combines research at Ricoh and Samsung Electronics with venture investing at ARCH and UTEC; he holds an engineering doctorate from Osaka University and an MBA from Chicago Booth.

Leads Vertex Ventures Japan and supports Japanese startups expanding overseas. He worked at Goldman Sachs, Deutsche Securities and UBS in Singapore before establishing an independent investment and financial advisory firm focused on management consulting and cross-border acquisitions.

Jason Prodouz was appointed president of enterprise supply chain operations at VSP Vision in January 2024, previously serving as chief product officer of Visionworks. His published remit includes integrating optical, eyewear and retail supply chains and delivering products suited to customer needs. He reports to the chief commercial officer under the announced structure. Exact service dates and current continuation beyond the published appointment are not inferred.

Michelle Skinner became VSP Vision chief provider and industry solutions officer in January 2024, leading a newly formed division supporting optometric providers and industry partnerships. The remit includes VSP Premier Edge, provider relations, enterprise strategic partnerships and PECAA. She previously served as chief growth officer and chief network officer. The dated primary appointment supports this affiliation; no full October 2026 company staff directory was published.

Scott Hopeck was appointed to VSP Vision’s new chief commercial officer role in January 2024, overseeing commercial strategy, supply-chain operations, sales and global business development. Before joining VSP he spent nearly twenty years at iHeartMedia and most recently served as a division president, leading business operations, sales, strategy and culture. This is a source-published appointment; continued October 2026 service was not independently confirmed by a complete current directory.

Scott Nehs was appointed VSP Vision chief legal officer and general counsel in May 2025, succeeding retired Chris Warren. His remit includes legal affairs, regulatory compliance, government affairs and corporate risk. He previously served as Blue Cross Blue Shield Association senior vice president, general counsel and corporate secretary, and in senior PepsiCo legal, government-affairs and compliance roles. He holds a JD from the University of Wisconsin and a BA from Northwestern University.

Michele Andrews, OD, became VSP Vision chief medical officer in March 2026, providing clinical oversight and helping develop and monitor accessible eye-care programs. She previously served as CooperVision vice president of marketing and professional affairs, executive vice president of professional services at ForEyes Optical, and in EyeMed Vision Care and LensCrafters leadership. She began as a practicing optometrist after receiving her doctorate from the Illinois College of Optometry.

Nicola Zotta returned to VSP Vision in January 2026 as president of eyewear and managing director of Marchon and Marcolin, following the group’s Marcolin acquisition. He was Artsana Group CEO from 2022 and earlier served as Marchon president from 2016 to 2022. He joined Marchon in 2009 as vice president and managing director of EMEA and APAC after more than a decade of senior roles with Safilo. His current role supersedes an uninterrupted-current interpretation of the older Marchon presidency.

Dave Plevyak was appointed VSP Vision chief insurance officer in January 2026, leading the not-for-profit VSP Vision Care benefits business. He joined VSP in 1992 and most recently led its financial planning and analysis as senior vice president of finance. His earlier work includes finance, corporate development, e-commerce and international expansion. He holds a finance bachelor’s from Santa Clara University and a master’s in economics and international finance from Claremont Graduate University.

Michael Guyette is president and CEO of VSP Vision, explicitly confirmed in the company’s January and March 2026 leadership announcements. He leads the vision-health corporate group formerly known as VSP Global. His public statements describe the group’s vision-benefits, care-delivery and eyewear strategy, including the integration of Marchon and Marcolin. The corporate leadership affiliation does not imply a personal NeuroVision investment.

Aqualateral is a Brooklyn-based investment platform focused on water security. It invests across asset classes and company stages in technologies that improve how water is accessed, treated, distributed and managed, including water reuse and desalination, treatment and diagnostics, flow measurement, leak detection, smart metering and irrigation, regenerative agriculture and stormwater management. The firm works with communities experiencing water insecurity to guide investment decisions and evaluate benefits for people as well as financial returns. It also provides invitation-only grants supporting underserved communities and early water solutions.

Natural Ventures is a venture investment firm focused on technology for global water and food security, with offices in Abu Dhabi and The Hague. It backs scalable technologies with commercial traction at the early growth stage, including connected and predictive management systems, decentralised production, resource recovery and reuse, efficient agriculture, decarbonisation and climate resilience. Its investors, water and agriculture specialists and operating partners support technical and commercial diligence, executive development, manufacturing and distribution partnerships, and expansion into Middle Eastern and Asian markets. The firm announced the first close of Natural Ventures Fund I in July 2024.

Contentsquare develops an AI-powered experience intelligence platform that helps companies understand and improve customer journeys on websites and mobile applications. Its software combines product and experience analytics, session replay, heatmaps, journey analysis, technical experience monitoring, customer feedback and conversation intelligence. Product, design, marketing and engineering teams use these behavioural insights to identify friction, investigate technical problems, prioritise improvements and measure customer engagement and conversion. Founded in 2012 by Jonathan Cherki, the company brings Contentsquare, Heap and Hotjar capabilities together in its platform.

Descartes Underwriting develops technology-driven parametric insurance for corporations and public bodies exposed to natural catastrophes, climate, cyber and other emerging risks. It combines machine-learning risk models with satellite, radar, IoT and other data to design coverage whose payout triggers are defined in advance, helping clients receive liquidity quickly after a qualifying event. Working with brokers and third-party risk carriers, it covers exposures including floods, drought, tropical cyclones, earthquakes, wildfire and agricultural losses. Descartes Underwriting SAS is a French insurance intermediary and managing general agent; its separately licensed subsidiary Descartes Insurance is a risk carrier.

Previously led Alternative Risk Transfer for Asia Pacific at Marsh. Established Descartes’ Sydney office and helped launch its Hong Kong and Tokyo offices.

Previously underwrote German risks at Chubb and worked in catastrophe analysis at R+V Re.

Previously spent more than twelve years in strategy consulting at Oliver Wyman, leading transformation and commercial effectiveness programmes for international insurers.

Founded Contentsquare in 2012 from a student project focused on improving digital experiences and later relocated to New York to expand the company internationally.

Previously developed weather and energy insurance products at AXA Global Parametrics and worked in modelling and actuarial research at AXA Corporate Solutions. Also leads the separately licensed Descartes Insurance subsidiary.

Previously held financial planning and controlling roles at Allianz, following experience at Deloitte, Natixis and PwC. His insurance finance experience includes capital management, accounting and mergers and acquisitions.

Previously worked at AXA Corporate Solutions and AXA Global Parametrics across data science, underwriting and business development.

Co-founded Descartes Underwriting after leading AXA Global Parametrics. Previously worked in Oliver Wyman’s financial-services practice and led property-and-casualty strategy at AXA.

Previously worked on agricultural IoT deployments at Phytech and crop insurance at Crop Risk Underwriting. Studied agricultural science and chemistry.

VSP Vision is the vision-health corporate group formerly branded VSP Global, headquartered in Rancho Cordova, California. Its March 31, 2022 issuer announcement explicitly confirms the group rebrand. The group traces its origins to 1955 and brings together vision benefits, eye-care services, eyewear and practice technology. Vision Service Plan, the California nonprofit parent, and the operating corporations are distinct legal entities: the December 2024 organizational chart submitted to Oregon regulators lists Vision Service Plan (CA) above entities including VSP Global, Inc., VSP Optical Group, Inc., Eyefinity, Inc., Marchon Eyewear and Visionworks. This profile represents the public corporate group; it does not assert that every subsidiary is nonprofit or identify an unpublished subscribing subsidiary. In May 2018 NeuroVision Imaging explicitly named VSP Global among institutional investors in its actual USD11.2 million Series C first close, connecting the group to retinal imaging and Alzheimer’s-detection technology. The intended USD15 million round total is not additional closed proceeds, and the group’s individual allocation was not disclosed. VSP’s Global Innovation Center also explores eye-health technology and AI, but accelerator participation, research collaborations, provider relationships and charitable support are not automatically monetary investments. VSP Ventures is an optometric-practice transition/acquisition business, rather than a verified external LP venture fund. Public 2026 appointments include Dave Plevyak as chief insurance officer, Nicola Zotta as president of eyewear and managing director of Marchon and Marcolin, and Michele Andrews as chief medical officer; Michael Guyette remains president and CEO. The public press archive provides additional dated leadership affiliations, which are individually qualified where a comprehensive current roster or continuation could not be verified. Financial statements are offered through a registration-controlled dataroom, so no undisclosed corporate borrowing, private equity raise, external fund corpus or investment-budget figure is invented. December 2025 Marcolin acquisition and other operating-company acquisitions are distinguished from new corporate funding.

Christoph Mandl is publicly listed by the Austrian Research Promotion Agency FFG as Head of Corporate Communications. Leads FFG corporate communications and is named contact on its official corporate-design toolkit. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Erich Stark is publicly listed by the Austrian Research Promotion Agency FFG as Head of Finance. Leads FFG central finance services. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Heidrun Schöfnagel is publicly listed by the Austrian Research Promotion Agency FFG as Head of Human Resources and Organisation. Leads FFG central human-resources and organisation services. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Andreas Wildberger is publicly listed by the Austrian Research Promotion Agency FFG as Head of Operations Management. Leads FFG Operations Management department. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Christian Hopp is publicly listed by the Austrian Research Promotion Agency FFG as Head of Legal, Compliance and Internal Audits. Leads FFG central legal, compliance and internal-audit services. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Michael Binder is publicly listed by the Austrian Research Promotion Agency FFG as Head of Strategy, Data Analysis and Business Development. Leads the FFG strategy, data analysis and business-development staff unit. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Claudia Hofmann-Turek is publicly listed by the Austrian Research Promotion Agency FFG as Head of Project Controlling and Audit. Leads FFG project controlling and audit; separately heads Research and Development Allowance unit. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Andreas Geisler is publicly listed by the Austrian Research Promotion Agency FFG as Head of Aeronautics and Space Agency. Leads FFG Agentur für Luft- und Raumfahrt, the Austrian interface for aeronautics and space research support. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Margit Noll is publicly listed by the Austrian Research Promotion Agency FFG as Head of European and International Programmes. Leads FFG European and international research-programme department. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Emmanuel Glenck is publicly listed by the Austrian Research Promotion Agency FFG as Head of Thematic Programmes. Leads FFG Thematische Programme department. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Birgit Tauber is publicly listed by the Austrian Research Promotion Agency FFG as Head of General Programmes. Leads FFG Basisprogramme, the agency department supporting industry-related applied R&D projects. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Silvia Laimgruber is publicly listed by the Austrian Research Promotion Agency FFG as Head of Structural Programmes. Leads FFG Strukturprogramme department. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

NanoVoxel GmbH is a Vienna contract manufacturer that designs and produces high-precision micro-components for medical devices, biotechnology, electronics and industrial engineering. It combines two-photon polymerization 3D printing with micro-injection molding, casting, micro-assembly and engineering consulting, choosing processes and materials for customers’ prototypes and larger production runs. Its capabilities cover complex three-dimensional structures, narrow channels and small features that are difficult to make with conventional machining. Applications include microfluidic chips and masters, micro-endoscopes, valves, microneedles, dispensing nozzles, microconnectors and miniature mechanical components. It also provides dimensional analysis using techniques such as laser 3D profilometry, scanning electron microscopy and micro-computed tomography. Registered in Austria in 2022, NanoVoxel serves researchers and product developers rather than selling an independently approved clinical therapy or diagnostic system.

NanoVoxel application engineer quoted in its supplier Onshape’s published customer case study about micro-part design, prototyping and remote CAD collaboration. This source-qualified affiliation is additional to the issuer’s two-person public leadership directory.

Thomas A. Henzinger is publicly listed by the Austrian Research Promotion Agency FFG as Consultative member, Supervisory Board. Published statutory consultative member under section6(4) FFG Act and chair of FORWIT research, science, innovation and technology development council. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Eastend Ventures is an Adelaide venture-capital firm investing in early-stage B2B technology companies in South Australia, Western Australia and Queensland, with selective investments elsewhere in Australia. It backs AI software and infrastructure, defence and industrial analytics, cybersecurity, climate technology, agriculture and healthcare technology. It helps founders commercialize products, build governance and teams, expand internationally and pursue trade-sale exits. Its platform runs venture funds, co-investment syndicates and dedicated funds for institutions; the operating company is Eastend Ventures Pty Ltd.

Golden Sparrow is a US-domiciled venture-capital firm backing Indian-origin founders building deep technology and enterprise AI for global markets. It makes pre-seed and seed investments across the India–US corridor in semiconductor technology, AI infrastructure and applications, defence electronics and autonomy, space components, robotics and biotechnology platforms. Its operating and venture partners help founders with product development, go-to-market strategy, commercialization and fundraising.

Heinz W. Engl is publicly listed by the Austrian Research Promotion Agency FFG as Consultative member, Supervisory Board. Published statutory consultative member under section6(4) FFG Act and chair of Austrian Science Fund FWF supervisory board. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Jo Chaturvedi-Durant is published by VU Venture Partners as Venture Partner - Asia-Pacific. The official professional biography states: Has over 16 years’ experience in the global investment management industry. Her experience includes US investment managers like Morgan Stanley, J.P. Morgan, and volunteers on the investment screening committees for impact funds. Is VC in residence at ThincLab - University of Adelaide, Australia. Has an academic background in International Business law and Behavioural economics. She has as authored thought pieces on macro and behavioral economics, retirement investing, asset allocation trends and impact of innovative technologies on the economy. Has extensive experience investing in and supporting portfolio companies across frontier tech, has held with executive and non-executive Board roles as well as advises founders, investors, accelerators, social enterprises and not for profit organizations.

MorphoMed is a Vienna-based preclinical medical-technology company developing biodegradable silk biomaterial implants for tissue regeneration. Its silk scaffolds are designed to support tendon and ligament repair, with rotator-cuff repair identified as its first medical indication in a 2026 company recruitment posting. Its wider development work includes cruciate-ligament grafts, nerve guidance conduits and methods for concentrating a patient’s own regenerative cells. The company develops and tests materials that provide a temporary structure for new tissue to grow as the implant degrades; published rotator-cuff results are from animal studies, rather than approved clinical use.

Biomaterials scientist and professor at UAS Technikum Wien who develops silk-fibroin technologies for regenerative implants, tendon and ligament repair, and nerve guidance conduits.

Life-science executive and chemist managing MorphoMed’s development of regenerative medical devices. Named CEO in the company’s 2026 recruitment posting and managing director in the Austrian register.

Sarah Ganss is publicly listed by the Austrian Research Promotion Agency FFG as Staff-council delegate, Supervisory Board. Published FFG employee representative on supervisory board. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Alexander Kosz is publicly listed by the Austrian Research Promotion Agency FFG as Staff-council delegate, Supervisory Board. Published FFG employee representative on supervisory board. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Markus Hinterwallner is publicly listed by the Austrian Research Promotion Agency FFG as Staff-council delegate, Supervisory Board. Published FFG employee representative on supervisory board. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Monika Egger-Fuchs is publicly listed by the Austrian Research Promotion Agency FFG as Staff-council delegate, Supervisory Board. Published FFG employee representative on supervisory board. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

ImageBiopsy Lab, operated by Vienna-based IB Lab GmbH, develops AI software that analyzes musculoskeletal medical images for radiologists and orthopedic clinicians. Its modular IB Lab ZOO platform integrates with PACS and RIS systems and returns standardized measurements and reports from X-rays and CT images. Applications include knee osteoarthritis assessment, pediatric bone-age estimation, lower-limb alignment and hip measurements, scoliosis assessment, and opportunistic screening for vertebral fractures and low bone mineral density. Its portfolio supports bone-health screening, diagnosis, surgical planning and follow-up, including analysis around hip and knee implants. The FDA has cleared its KOALA knee-analysis software and IB Lab LAMA leg-measurement software; regulatory status is specific to the product and market. Founded in 2016, the company has its headquarters in Vienna and publishes a separate US subsidiary, ImageBiopsy Lab, Inc., in New Jersey.

ImageBiopsy Lab co-founder leading operations and financial procedures, platform design and collaborations.

Leads ImageBiopsy Lab’s financial planning, corporate governance, legal and human-resource processes.

Henriette Spyra is publicly listed by the Austrian Research Promotion Agency FFG as Member, Supervisory Board. Official current governance listing associates her with Federal Ministry for Innovation, Mobility and Infrastructure. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Linda Keizer is publicly listed by the Austrian Research Promotion Agency FFG as Member, Supervisory Board. Official current governance listing associates her with Austrian Trade Union Federation. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Maria Bürgermeister-Mähr is publicly listed by the Austrian Research Promotion Agency FFG as Staff-council delegate, Supervisory Board. Published FFG employee representative on supervisory board. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Michael Soder is publicly listed by the Austrian Research Promotion Agency FFG as Member, Supervisory Board. Official governance listing associates him with Vienna Chamber of Labour. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Named as an ImageBiopsy Lab co-founder in its January 2024 history and as Chief Commercial Officer in its March 2022 article. This is a dated historical affiliation; the current executive directory assigns commercial leadership to Richard Ljuhar.

Founder of ImageBiopsy Lab responsible for innovation, sales, strategic partnerships and key accounts.

Leads ImageBiopsy Lab’s computer-vision and machine-learning technology, from design and specification to implementation.

Christian Grabner is publicly listed by the Austrian Research Promotion Agency FFG as Member, Supervisory Board. Official governance listing associates him with Knapp AG. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Gertrude Tumpel-Gugerell is publicly listed by the Austrian Research Promotion Agency FFG as Member, Supervisory Board. Former member of the European Central Bank executive board; current German FFG page lists her as ordinary supervisory member, not current chair. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Günter Rübig is publicly listed by the Austrian Research Promotion Agency FFG as Member, Supervisory Board. Official governance listing associates him with Rübig GmbH & Co KG. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Hannes Bardach is publicly listed by the Austrian Research Promotion Agency FFG as Member, Supervisory Board. Official FFG governance listing associates him with Frequentis AG. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Johann Marihart is publicly listed by the Austrian Research Promotion Agency FFG as Deputy Chairman, Supervisory Board. Current official governance publication identifies him as deputy supervisory chairman. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Karin Tausz is publicly listed by the Austrian Research Promotion Agency FFG as Managing Director. Has led FFG since September 2023; Vienna economics graduate with strategy and mobility-sector roles at Magna Steyr, SBB and ÖBB; published Austro Control supervisory chair and AIT board affiliations. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Klaus Pseiner is publicly listed by the Austrian Research Promotion Agency FFG as Chairman, Supervisory Board. Current official German page identifies him as supervisory chairman; stale English lists another chair and is not used as current appointment evidence. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Ulrike Domany-Funtan is publicly listed by the Austrian Research Promotion Agency FFG as Member, Supervisory Board. Official governance listing associates her with fit4internet. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

Henrietta Egerth is publicly listed by the Austrian Research Promotion Agency FFG as Managing Director. Has led FFG since September 2004; studied commercial science in Linz, worked in Brussels, the Federation of Austrian Industry and Austrian Ministry of Economics and Labour. This is an institutional governance or employment role, not an individual venture investment. Appointment date is undisclosed unless specifically stated in the biography.

The Austrian Research Promotion Agency FFG is Austria’s national funding institution for industry-related research, development and innovation. Its exact legal entity is Österreichische Forschungsförderungsgesellschaft mbH, registered FN252263a at the Vienna Commercial Court, headquartered at Sensengasse1,1090Vienna. Its official legal notice states it was established September1,2004 under the FFG Act and is wholly owned by the Republic of Austria. Shareholder rights are exercised by the Federal Ministry for Innovation, Mobility and Infrastructure and the Federal Ministry for Economy, Energy and Tourism. FFG is retained as an institutional organization, distinct from Austria Wirtschaftsservice, Austrian Science Fund FWF, EU grant agencies and unrelated companies using the FFG abbreviation. FFG funds, advises and connects innovative companies, universities and research institutions, evaluates research projects, and represents Austria in national and international bodies. Its published remit spans general company R&D, thematic and structural programmes, European and international programmes, and aeronautics and space. It acts as Austria’s national contact point for EU research programmes and interface to the European Space Agency. Support instruments differ by programme; research-result exploitation rights remain with recipients. Its relevance includes AI, deep technology, life sciences and neuroscience research commercialization, without implying that every project is an equity investment or an approved clinical product. The current German governance and leadership page identifies Henrietta Egerth and Karin Tausz as managing directors and Klaus Pseiner as supervisory chairman. The public governance and senior-management roster comprises31named people and32roles, including supervisory members, staff-council representatives, statutory consultative members, department heads and central-service heads. The English page retains outdated supervisory appointments and department roles; it is not used as the current-role authority. The wider staff directory is distinct from this published leadership/governance scope. Agency annual disbursements, appropriations, programme budgets and cumulative project support describe public research funding rather than private-LP fund closes or manager AUM. No closed venture fund is inferred. Brightmind’s own undated fundraising page reports cumulative EUR3.3million raised, including EUR2.4million non-dilutive support from FFG and aws together; it does not allocate an individual FFG ticket, award date or programme. Only a qualified non-dilutive support relationship is supported, not an additional EUR2.4million FFG-only cash award. The issuer’s legal-status/funding chronology remains subject to its separate company audit.

Oost NL is the regional development and investment agency for Gelderland and Overijssel in the eastern Netherlands. It finances innovative startups and growth companies, manages regional and public investment funds, and helps entrepreneurs develop technology, find partners and expand internationally. Its work spans sustainable food, health technology, industrial and digital technologies, smart energy and the circular economy. The Capital team invests alongside private co-investors, while Business Development and International teams support innovation projects, company growth and foreign investment into the region. Oost NL operates on behalf of its public shareholders: the Dutch Ministry of Economic Affairs, the provinces of Gelderland and Overijssel, and the University of Twente. Its legal entity is Oost NL - Ontwikkelingsmaatschappij Oost-Nederland NV.